NCT00563758View on ClinicalTrials.gov

A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy, Safety and Tolerability of Tegaserod 2 mg Bid vs Placebo in Patients With Chronic Constipation

NATerminatedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

December 31, 2004

Study Completion Date

February 28, 2006

Conditions
ConstipationChronic Disease
Interventions
DRUG

tegaserod

Trial Locations (1)

Unknown

Queen Mary Hospital, Hong Kong

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Hospital Authority, Hong Kong

OTHER_GOV

NCT00563758 - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy, Safety and Tolerability of Tegaserod 2 mg Bid vs Placebo in Patients With Chronic Constipation | Biotech Hunter | Biotech Hunter